Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca To Boost Clinical Trial Investment In Japan By Third (Japan)

This article was originally published in PharmAsia News

Executive Summary

AstraZeneca says it intends to place more than 20 drug candidates in clinical trials in Japan next fiscal year, backed by a $90 billion investment. CEO David Brennan said the investment would be 30 percent more than the company spent this year on Japan-based research, breaking a go-slow attitude the firm had in the past towards Japan. The drug candidates include ones for cancer and heart disease. This fiscal year, the firm tested fewer than 20 drugs for Japanese approval. (Click here for more - may require paid subscription

You may also be interested in...



COVID-19 Vaccine Could Cost As Little As $10 A Dose, Says Janssen

Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.

Austria’s Apeiron To Attack COVID-19 At Its Entry Point

Apeiron Biologics has fashioned a recombinant version of the enzyme to which SARS-CoV-2 is thought to bind, and with governmental help has started a Phase II study in Austria, Germany and Denmark. 
 
 
 

 

Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics

Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.

UsernamePublicRestriction

Register

SC065957

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel